KYAN Technologies Pte Ltd Press Releases

• Published on January 24, 2025 - 00:04 GMT

  KYAN Technologies’ platform used to find drug combination and potential biomarker in radioresistant cancer study

  SINGAPORE, January 23, 2025 /⁨EINPresswire.com⁩/ -- KYAN Technologies Pte. Ltd. (“KYAN”) announces the publication of study results in Experimental Hematology & Oncology, with the publication title: “Combinatorial functionomics identifies HDAC6- …

  Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
• Published on December 5, 2024 - 07:20 GMT

  KYAN Technologies to Present Predictive Cancer Response Test Immunotherapy Data at the 66th ASH Annual Meeting

  SINGAPORE, SINGAPORE, December 4, 2024 /⁨EINPresswire.com⁩/ -- KYAN Technologies Pte. Ltd. (“KYAN”), a biotech company that has developed clinically utilized functional precision medicine technology, today announced a poster presentation at the 66th …

  Distribution channels: Conferences & Trade Fairs, Healthcare & Pharmaceuticals Industry ...
• Published on December 2, 2024 - 20:20 GMT

  KYAN Technologies’ cancer response prediction platform shows high accuracy for leukemia in clinical study publication

  SINGAPORE, SINGAPORE, December 2, 2024 /⁨EINPresswire.com⁩/ -- KYAN Technologies Pte. Ltd. (“KYAN”) announces the publication of study results in Cancer Medicine, with the publication title: “A Combinatorial Functional Precision Medicine Platform for Rapid …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on September 18, 2024 - 06:31 GMT

  KYAN Technologies to Present New Data at 2024 Rivkin Center and AACR Ovarian Cancer Research Symposium

  Highlighted results for ovarian cancer patients include differential interpatient sensitivities and similar response for multiple intrapatient sample sites. SINGAPORE, SINGAPORE, SINGAPORE, September 17, 2024 /⁨EINPresswire.com⁩/ -- KYAN Technologies will …

  Distribution channels: Business & Economy, Conferences & Trade Fairs ...
• Published on March 27, 2024 - 17:35 GMT

  KYAN Technologies to Present New Data in Oral Minisymposium and Posters at AACR 2024 Annual Meeting

  Data presented will be on clinical concordance for sarcoma, KRAS inhibitor combinations, and patient derived organoids in colorectal cancer. SINGAPORE, SINGAPORE, March 27, 2024 /⁨EINPresswire.com⁩/ -- KYAN Technologies Pte Ltd (KYAN), a biotech company …

  Distribution channels: Companies, Conferences & Trade Fairs ...
• Published on December 4, 2023 - 06:21 GMT

  KYAN Technologies to Present AML Concordance Data at the 65th ASH Annual Meeting and Exposition

  Clinical Acute Myeloid Leukemia Data Shows KYAN’s Strengthened Functional Assay Expertise and Application in Hematological Cancers SINGAPORE, December 4, 2023 /⁨EINPresswire.com⁩/ -- KYAN Technologies Private Limited (‘KYAN”), a combinatorial functional …

  Distribution channels: Business & Economy, Conferences & Trade Fairs ...
• Published on November 14, 2023 - 07:22 GMT

  KYAN Technologies Announces Presentation at the 2023 AACR-KCA Joint Conference on Precision Medicine in Cancer

  Presenting combinatorial ex vivo evaluation of 3D patient-derived organoids in colorectal cancer SINGAPORE, November 14, 2023 /⁨EINPresswire.com⁩/ -- KYAN Technologies, a clinical-stage, functional precision medicine company, today announced a poster …

  Distribution channels: Business & Economy, Conferences & Trade Fairs ...
• Published on October 10, 2023 - 00:16 GMT

  KYAN Technologies to Present Functional Combinatorial Precision Medicine Platform Data at 2023 AACR-NCI-EORTC Conference

  Clinical concordance data for AML and NHL along with preclinical data on targeting KRAS to be presented SINGAPORE, SINGAPORE, October 10, 2023 /⁨EINPresswire.com⁩/ -- KYAN Technologies Pte Ltd (“KYAN”), an innovative small data AI biotech company, today …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on September 30, 2023 - 00:08 GMT

  Advancing Claudin-1 Expression Research with Cutting-edge Technologies

  KYAN Technologies,Alentis Therapeutics,and CELLphenomics Join Forces Combining Cutting-edge Optim.AI™ and PD3D® Models to Advance Claudin-1 Expression Research SINGAPORE, SINGAPORE, September 30, 2023 /⁨EINPresswire.com⁩/ -- KYAN Technologies, a vanguard …

  Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
• Published on May 29, 2023 - 08:22 GMT

  

  KYAN Technologies obtains MOH approval in Singapore and will offer OPTIM.AI™ for cancer patients

  OPTIM.AI™ is a Functional Precision Medicine Test that supports physicians to personalize treatments SINGAPORE, May 29, 2023 /⁨EINPresswire.com⁩/ -- KYAN Technologies Pte Ltd, a leading biotechnology company headquartered in Singapore, is proud to …

  Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...
• Published on April 18, 2023 - 06:27 GMT

  KYAN Therapeutics to Present Poster with New Data from Lymphoma Clinical Study on Effective Combinations at AACR 2023

  Clinical data from evaluation of functional combinatorial precision oncology platform highlights effective sub-group specific drug combinations SINGAPORE, April 18, 2023 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics, a biotech company focused on functional …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on October 27, 2022 - 07:17 GMT

  KYAN Therapeutics raises USD $5.0M for its Pre-Series A funding

  Singapore headquartered KYAN to launch personalized treatment assay for cancer patients following publication of landmark study with leading cancer centers SINGAPORE, October 27, 2022 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics, a biotech company with novel …

  Distribution channels: Business & Economy, Companies ...
• Published on October 19, 2022 - 22:41 GMT

  Publication of Clinical Study Shows Positive Benefits of KYAN's Clinical Decision Support Platform for Cancer Patients

  In largest prospective study to date of guided therapy for relapsed/refractory non-Hodgkin lymphoma patients, 59% had improved PFS over their previous treatment SINGAPORE, October 19, 2022 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics, a biotech company with …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on October 6, 2022 - 07:56 GMT

  KYAN Therapeutics Announces Presentation of Clinical Utility of Ex-Vivo Platform at ASTRO and CTOS by Collaborators

  SINGAPORE, October 6, 2022 /⁨EINPresswire.com⁩/ -- Data on the feasibility of identifying therapeutic options in head and neck cancers and sarcoma with KYAN’s analytical ex vivo drug screening platform will be presented at the Annual Meetings of the …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on September 17, 2022 - 06:11 GMT

  KYAN Therapeutics' technology platform identifies novel and effective nucleic acid therapies for MYC-driven liver cancer

  Study published in Bioengineering & Translational Medicine SINGAPORE, SINGAPORE, September 17, 2022 /⁨EINPresswire.com⁩/ -- MYC is a transcription factor that is dysregulated in over 70% of human cancers, making it an important target that …

  Distribution channels: Business & Economy, Companies ...
• Published on May 9, 2022 - 11:04 GMT

  

  KYAN Therapeutics and Curie Oncology Announce Strategic Collaboration to Provide Personalized Cancer Test in Singapore

  KYAN Therapeutics uses small data AI in a proprietary phenotypic drug sensitivity assay to guide patient treatment for cancer patients with high and unmet needs SINGAPORE, May 9, 2022 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics teams up with Curie Oncology …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on April 28, 2022 - 06:20 GMT

  

  KYAN Therapeutics and Aesculape CRO Partner to Offer Drug Development Biopharma Services

  SINGAPORE, April 28, 2022 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics, Inc. (KYAN) and Aesculape CRO (Aesculape) announce plans to offer drug development optimization services for Pharmaceutical and Biotech companies. Studies in recent years estimate that …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on November 23, 2021 - 12:10 GMT

  KYAN Therapeutics Announces Presentation by Collaborators on Personalized Oncology Platform at 63rd ASH Annual Meeting

  Clinical data shows that ex-vivo drug sensitivity platform can help guide clinicians’ treatment of relapsed/refractory cancer patients SINGAPORE, November 23, 2021 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics Inc., a biotech company focused on improved …

  Distribution channels: Companies, Conferences & Trade Fairs ...
• Published on November 11, 2021 - 10:07 GMT

  KYAN Therapeutics Presents Preclinical Data on Novel HDACi Targeting KRAS-mutated Cancers at AACR-KCA Conference

  First in class, selective Class II HDAC inhibitor shows combinatorial effect against KRAS mutations in prostate and pancreatic cancer SINGAPORE, November 11, 2021 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics Inc., a frontier biotech company with a novel drug …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
• Published on November 8, 2021 - 12:43 GMT

  

  KYAN Therapeutics announces Hugo Saavedra as CEO

  SINGAPORE, November 8, 2021 /⁨EINPresswire.com⁩/ -- KYAN Therapeutics Inc. (“KYAN”), a frontier biotech company with a novel drug-dose combination optimization platform, Optim.AI, has appointed Hugo Saavedra as Chief Executive Officer effective on January …

  Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...